ROCHE HOLDING AG-BR (RHO.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:RHO - CH0012032113 - Common Stock
363.6 EUR
-1.4 (-0.38%)
Overall RHO gets a fundamental rating of 6 out of 10. We evaluated RHO against 52 industry peers in the Pharmaceuticals industry. RHO scores excellent on profitability, but there are some minor concerns on its financial health. RHO has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
RHO had positive earnings in the past year.
RHO had a positive operating cash flow in the past year.
In the past 5 years RHO has always been profitable.
RHO had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
RHO has a better Return On Assets (9.95%) than 73.08% of its industry peers.
RHO has a better Return On Equity (32.88%) than 84.62% of its industry peers.
RHO has a Return On Invested Capital of 24.24%. This is amongst the best in the industry. RHO outperforms 92.31% of its industry peers.
RHO had an Average Return On Invested Capital over the past 3 years of 23.72%. This is significantly above the industry average of 13.72%.
The last Return On Invested Capital (24.24%) for RHO is above the 3 year average (23.72%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.95% | ||
| ROE | 32.88% | ||
| ROIC | 24.24% |
ROA(3y)11.64%
ROA(5y)13.32%
ROE(3y)36.55%
ROE(5y)41.17%
ROIC(3y)23.72%
ROIC(5y)23.71%
1.3 Margins
The Profit Margin of RHO (15.31%) is comparable to the rest of the industry.
In the last couple of years the Profit Margin of RHO has declined.
Looking at the Operating Margin, with a value of 33.79%, RHO belongs to the top of the industry, outperforming 86.54% of the companies in the same industry.
In the last couple of years the Operating Margin of RHO has remained more or less at the same level.
The Gross Margin of RHO (73.92%) is better than 69.23% of its industry peers.
RHO's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.79% | ||
| PM (TTM) | 15.31% | ||
| GM | 73.92% |
OM growth 3Y4.01%
OM growth 5Y0.18%
PM growth 3Y-14.88%
PM growth 5Y-9.03%
GM growth 3Y2.22%
GM growth 5Y0.6%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so RHO is creating value.
The number of shares outstanding for RHO has been reduced compared to 1 year ago.
The number of shares outstanding for RHO has been reduced compared to 5 years ago.
Compared to 1 year ago, RHO has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 4.60 indicates that RHO is not in any danger for bankruptcy at the moment.
RHO has a better Altman-Z score (4.60) than 67.31% of its industry peers.
RHO has a debt to FCF ratio of 2.50. This is a good value and a sign of high solvency as RHO would need 2.50 years to pay back of all of its debts.
RHO's Debt to FCF ratio of 2.50 is fine compared to the rest of the industry. RHO outperforms 69.23% of its industry peers.
A Debt/Equity ratio of 1.06 is on the high side and indicates that RHO has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.06, RHO is doing worse than 65.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.06 | ||
| Debt/FCF | 2.5 | ||
| Altman-Z | 4.6 |
ROIC/WACC5.11
WACC4.74%
2.3 Liquidity
RHO has a Current Ratio of 1.29. This is a normal value and indicates that RHO is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.29, RHO perfoms like the industry average, outperforming 46.15% of the companies in the same industry.
A Quick Ratio of 1.02 indicates that RHO should not have too much problems paying its short term obligations.
RHO has a Quick ratio (1.02) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.02 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 5.19% over the past year.
RHO shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.39% yearly.
The Revenue has been growing slightly by 4.77% in the past year.
RHO shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.32% yearly.
EPS 1Y (TTM)5.19%
EPS 3Y-1.73%
EPS 5Y-1.39%
EPS Q2Q%8.5%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-1.24%
Revenue growth 5Y-0.32%
Sales Q2Q%3.67%
3.2 Future
Based on estimates for the next years, RHO will show a small growth in Earnings Per Share. The EPS will grow by 6.07% on average per year.
The Revenue is expected to grow by 3.19% on average over the next years.
EPS Next Y5.56%
EPS Next 2Y5.15%
EPS Next 3Y5.5%
EPS Next 5Y6.07%
Revenue Next Year2.32%
Revenue Next 2Y2.54%
Revenue Next 3Y2.72%
Revenue Next 5Y3.19%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 17.22, which indicates a rather expensive current valuation of RHO.
RHO's Price/Earnings ratio is a bit cheaper when compared to the industry. RHO is cheaper than 63.46% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.51, RHO is valued a bit cheaper.
RHO is valuated correctly with a Price/Forward Earnings ratio of 16.29.
Compared to the rest of the industry, the Price/Forward Earnings ratio of RHO is on the same level as its industry peers.
The average S&P500 Price/Forward Earnings ratio is at 23.13. RHO is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.22 | ||
| Fwd PE | 16.29 |
4.2 Price Multiples
RHO's Enterprise Value to EBITDA is on the same level as the industry average.
RHO's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.76 | ||
| EV/EBITDA | 12.12 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates RHO does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of RHO may justify a higher PE ratio.
PEG (NY)3.1
PEG (5Y)N/A
EPS Next 2Y5.15%
EPS Next 3Y5.5%
5. Dividend
5.1 Amount
RHO has a Yearly Dividend Yield of 2.94%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 2.20, RHO pays a bit more dividend than its industry peers.
Compared to an average S&P500 Dividend Yield of 2.00, RHO pays a bit more dividend than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.94% |
5.2 History
The dividend of RHO has a limited annual growth rate of 2.37%.
Dividend Growth(5Y)2.37%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
85.87% of the earnings are spent on dividend by RHO. This is not a sustainable payout ratio.
RHO's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP85.87%
EPS Next 2Y5.15%
EPS Next 3Y5.5%
FRA:RHO (12/30/2025, 7:00:00 PM)
363.6
-1.4 (-0.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners40.35%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap294.24B
Revenue(TTM)61.59B
Net Income(TTM)9.43B
Analysts70.37
Price Target349.14 (-3.98%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.94% |
Yearly Dividend10.88
Dividend Growth(5Y)2.37%
DP85.87%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.02%
PT rev (3m)2.29%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.01%
EPS NY rev (3m)-0.46%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.19%
Revenue NY rev (3m)-0.4%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.22 | ||
| Fwd PE | 16.29 | ||
| P/S | 4.45 | ||
| P/FCF | 20.76 | ||
| P/OCF | 14.21 | ||
| P/B | 9.56 | ||
| P/tB | 63.06 | ||
| EV/EBITDA | 12.12 |
EPS(TTM)21.12
EY5.81%
EPS(NY)22.32
Fwd EY6.14%
FCF(TTM)17.52
FCFY4.82%
OCF(TTM)25.58
OCFY7.04%
SpS81.71
BVpS38.05
TBVpS5.77
PEG (NY)3.1
PEG (5Y)N/A
Graham Number134.46
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.95% | ||
| ROE | 32.88% | ||
| ROCE | 30.98% | ||
| ROIC | 24.24% | ||
| ROICexc | 25.87% | ||
| ROICexgc | 40.74% | ||
| OM | 33.79% | ||
| PM (TTM) | 15.31% | ||
| GM | 73.92% | ||
| FCFM | 21.43% |
ROA(3y)11.64%
ROA(5y)13.32%
ROE(3y)36.55%
ROE(5y)41.17%
ROIC(3y)23.72%
ROIC(5y)23.71%
ROICexc(3y)28.94%
ROICexc(5y)29.11%
ROICexgc(3y)49.53%
ROICexgc(5y)49.86%
ROCE(3y)29.26%
ROCE(5y)30.68%
ROICexgc growth 3Y2.54%
ROICexgc growth 5Y-3.21%
ROICexc growth 3Y1.27%
ROICexc growth 5Y-3.5%
OM growth 3Y4.01%
OM growth 5Y0.18%
PM growth 3Y-14.88%
PM growth 5Y-9.03%
GM growth 3Y2.22%
GM growth 5Y0.6%
F-Score8
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.06 | ||
| Debt/FCF | 2.5 | ||
| Debt/EBITDA | 1.25 | ||
| Cap/Depr | 175.31% | ||
| Cap/Sales | 9.87% | ||
| Interest Coverage | 17.17 | ||
| Cash Conversion | 79.41% | ||
| Profit Quality | 140.01% | ||
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.02 | ||
| Altman-Z | 4.6 |
F-Score8
WACC4.74%
ROIC/WACC5.11
Cap/Depr(3y)132.99%
Cap/Depr(5y)129.62%
Cap/Sales(3y)7.8%
Cap/Sales(5y)8.42%
Profit Quality(3y)129.49%
Profit Quality(5y)117.9%
High Growth Momentum
Growth
EPS 1Y (TTM)5.19%
EPS 3Y-1.73%
EPS 5Y-1.39%
EPS Q2Q%8.5%
EPS Next Y5.56%
EPS Next 2Y5.15%
EPS Next 3Y5.5%
EPS Next 5Y6.07%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-1.24%
Revenue growth 5Y-0.32%
Sales Q2Q%3.67%
Revenue Next Year2.32%
Revenue Next 2Y2.54%
Revenue Next 3Y2.72%
Revenue Next 5Y3.19%
EBIT growth 1Y10.03%
EBIT growth 3Y2.72%
EBIT growth 5Y-0.14%
EBIT Next Year23.19%
EBIT Next 3Y10.25%
EBIT Next 5Y8.74%
FCF growth 1Y12.91%
FCF growth 3Y-2.8%
FCF growth 5Y-2.91%
OCF growth 1Y19.07%
OCF growth 3Y-1.42%
OCF growth 5Y-2.14%
ROCHE HOLDING AG-BR / RHO.DE FAQ
Can you provide the ChartMill fundamental rating for ROCHE HOLDING AG-BR?
ChartMill assigns a fundamental rating of 6 / 10 to RHO.DE.
What is the valuation status of ROCHE HOLDING AG-BR (RHO.DE) stock?
ChartMill assigns a valuation rating of 4 / 10 to ROCHE HOLDING AG-BR (RHO.DE). This can be considered as Fairly Valued.
How profitable is ROCHE HOLDING AG-BR (RHO.DE) stock?
ROCHE HOLDING AG-BR (RHO.DE) has a profitability rating of 8 / 10.
What is the valuation of ROCHE HOLDING AG-BR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for ROCHE HOLDING AG-BR (RHO.DE) is 17.22 and the Price/Book (PB) ratio is 9.56.
Can you provide the financial health for RHO stock?
The financial health rating of ROCHE HOLDING AG-BR (RHO.DE) is 6 / 10.